Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Conditions:   Nasopharyngeal Carcinoma;   Nasopharyngeal Cancer Intervention:   Drug: Fluzoparib and Camrelizumab Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials